InvestorsHub Logo
Followers 65
Posts 2382
Boards Moderated 0
Alias Born 01/16/2011

Re: None

Saturday, 08/08/2020 11:13:21 PM

Saturday, August 08, 2020 11:13:21 PM

Post# of 64546
What if ...

A/O today, Sat Aug-08-2020, "Three vaccines are in phase 3 of human clinical trials, which ensure effectiveness but also safety."

> University of Oxford/AstraZeneca
> Moderna
> Chinese company CanSino Biologics

FDA: Any vaccine will need to be at least 50 percent effective to be approved: that is, prevent infections in at least 50 percent of the people who receive it.

Hmmm, wish them well, but seems to be a rather low hallelujah bar.

TSOI: Current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune in reducing infection in individuals at high risk of COVID-19. [ClinicalTrials.gov Identifier: NCT04421391]; that is, to assess statistically significant increases in immune response activity within 5 days.

So, IF a vaccine(s) can identify, attack and neutralize a marauding COVID-19 virus with the tenacity of an OTC stock basher, great. There's a 50 percent (or hopefully greater) chance that'll happen.

IF QuadraMune can increase immune response to the degree that it neutralizes the COVID-19 virus naturally, the mind reels with the possibilities.

IF QM is given in conjunction with a vaccine, could it, would it extend the efficacy of the vaccine?

TSOI long

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News